Literature DB >> 6753240

Resistance of the prairie vole (Microtus ochrogaster) and the woodrat (Neotoma floridana), in Kansas, to venom of the osage copperhead (Agkistrodon contortrix phaeogaster).

C A de Wit.   

Abstract

Prairie vole (Microtus ochrogaster) serum has no anti-lysing or antibody activity against Osage copperhead (Agkistrodon contortrix phaeogaster) venom. However, the serum has an anti-hemorrhagic component, which significantly reduces the size of hemorrhage produced by the minimal hemorrhagic dose of venom and which blocks the minimal hemorrhagic dose at a dilution of 1/8. Woodrat (Neotoma floridana) serum also has an antihemorrhagic component which blocks the minimal hemorrhagic dose at a dilution of 1/32. When compared to similar sized rodents previously tested in Texas, the anti-hemorrhagic activity in the serum of the Kansas rodents is similar. This suggests that venom resistance in prey items of venomous snakes may be more common than thought previously.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6753240     DOI: 10.1016/0041-0101(82)90119-2

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  3 in total

1.  Venom variation and chemoreception of the viperid Agkistrodon contortrix: evidence for adaptation?

Authors:  Eli Greenbaum; Nadezhda Galeva; Michael Jorgensen
Journal:  J Chem Ecol       Date:  2003-08       Impact factor: 2.626

Review 2.  Convergent evolution of toxin resistance in animals.

Authors:  Jory van Thiel; Muzaffar A Khan; Roel M Wouters; Richard J Harris; Nicholas R Casewell; Bryan G Fry; R Manjunatha Kini; Stephen P Mackessy; Freek J Vonk; Wolfgang Wüster; Michael K Richardson
Journal:  Biol Rev Camb Philos Soc       Date:  2022-05-17

3.  Arizona bark scorpion venom resistance in the pallid bat, Antrozous pallidus.

Authors:  Bradley H Hopp; Ryan S Arvidson; Michael E Adams; Khaleel A Razak
Journal:  PLoS One       Date:  2017-08-30       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.